Aceragen (ACGN) SC 13D/A IDERA PHARMACEUTICALS / Pillar Pharmaceuticals 6 ownership change

Exhibit 99.3

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

Date: October 5, 2022

PILLAR PHARMACEUTICALS 6, L.P. CORPORATION
By: Pillar Invest Corporation, its general partner
By:	/s/ Youssef El Zein
	Name: Youssef El Zein
	Title: Director
PILLAR PARTNERS FOUNDATION, L.P.
By:	/s/ Youssef El Zein
	Name: Youssef El Zein
	Title: Director
PILLAR INVEST CORPORATION
By:	/s/ Youssef El Zein
	Name: Youssef El Zein
	Title: Director
/s/ Abude Umari
Abude Umari
/s/ Youssef El Zein
Youssef El Zein